Vienna, Austria-based biotech firm Haplogen has entered into a multi-year drug discovery and development collaboration with German pharma major Bayer (BAYN: DE) to identify new therapeutics with applications in pulmonary diseases such as chronic obstructive pulmonary disease (COPD).
The announcement was made by German biotech firm Evotec (EVT: Xetra), which has been collaborating with Haplogen since 2012, and saying the companies have collectively built a robust portfolio of pulmonary therapeutic programs based on the industry-leading drug discovery platforms and know-how of both companies. The target-based approach will now be broadened under the terms of the new Haplogen collaboration with Bayer.
Terms of the deal
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze